Fosamax and Osteonecrosis of the Jaw: Causation, Risk, and What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Communication to Targeted Risk Assessment

The legacy of general health and science communication has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad heritage, the dissemination of information regarding pharmaceutical interventions has been a central pillar, guiding both clinical practice and patient awareness. As the domain of mass production evolves, the focus naturally shifts from generalized health advisories to more specific, context-driven inquiries. In this transition, the bridge concept emerges from the need to translate broad health principles into targeted occupational and environmental exposure assessments. The target query concerning Fosamax and osteonecrosis of the jaw causation exemplifies this pivot: it moves from a general health context—where drug safety and side effects are discussed in population-level terms—to a focused examination of exposure risk in specific settings. This shift acknowledges that while general health information provides a baseline, the nuances of causation and risk require a more granular approach, particularly when considering prolonged or high-level exposure scenarios. Thus, the transition from legacy heritage to occupational exposure concern is not a departure but a refinement, applying established scientific communication frameworks to address precise, real-world questions about pharmaceutical impact and safety in specialized contexts.

Bridging General Health Knowledge to Specific Exposure Concerns

Building on the foundation of general health communication, this section bridges the gap between broad pharmaceutical safety information and the specific inquiry into Fosamax and osteonecrosis of the jaw (ONJ). The transition from legacy heritage to occupational exposure concern is not a departure but a refinement, applying established scientific communication frameworks to address precise, real-world questions about pharmaceutical impact and safety in specialized contexts. Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a known adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). ONJ is a condition characterized by exposed, necrotic bone in the jaw that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation often involves pain, swelling, and non-healing extraction sockets. Diagnosis relies on clinical examination and imaging, with the condition being distinct from other jaw pathologies.

Evidence for Causation: Pathophysiology and Temporal Association

The pathophysiology of ONJ in the context of bisphosphonate use is not fully understood, but multiscale characterization of jawbone tissue provides comprehensive information that can help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077). This suggests that the unique structure and remodeling dynamics of the jawbone may contribute to its vulnerability. The risk of ONJ with Fosamax is documented in FDA-approved labeling. Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Risk Magnitude and Population-Level Data

In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized adverse effect, its occurrence in clinical trials was not statistically elevated compared to placebo, indicating it is a rare event. Population-level data further clarify the risk magnitude. Among female patients treated for osteoporosis, ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702). This study, conducted in the United Kingdom Clinical Practice Research Datalink among cancer-free female patients aged 40-89, underscores that while the relative risk increases with longer exposure, the absolute risk remains small. Causation considerations for affected patients involve establishing a temporal relationship between Fosamax use and ONJ onset, excluding other etiologies such as cancer, radiation therapy, or other medications. The presence of known risk factors, particularly invasive dental procedures, can complicate attribution. The FDA label advises discontinuation if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Clinical Management and Adequacy of Warnings

For patients who develop ONJ, management typically involves conservative measures, including oral antimicrobial rinses, avoidance of surgical intervention, and discontinuation of the bisphosphonate when feasible. Adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's prescribing information. The label includes a specific section on osteonecrosis of the jaw (Section 5.4) that describes the condition, associated risk factors, and recommendations for dental care (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that the optimal duration of use has not been determined and recommends considering drug discontinuation after 3 to 5 years for low-risk patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the rarity of ONJ and the similarity of symptom rates in placebo groups may contribute to underrecognition in clinical practice. Patients and healthcare providers should be aware of the risk, especially when planning invasive dental procedures, and consider preventive dental care before initiating bisphosphonate therapy. In summary, Fosamax is associated with a rare but documented risk of ONJ, with evidence supporting a causal relationship through temporal association, biological plausibility (jawbone-specific responses), and dose-duration effects. The risk is low in absolute terms but increases with prolonged use. Warnings in the prescribing information are present but may require careful communication to ensure informed decision-making.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that has been associated with osteonecrosis of the jaw (ONJ), a rare condition where bone tissue in the jaw dies and becomes exposed. The FDA label includes a specific warning about this risk. Studies show that the risk increases with longer duration of use, but absolute risk remains low (e.g., about 0.05% after 5 years) (https://pubmed.ncbi.nlm.nih.gov/39400702).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease. The risk may increase with longer exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is ONJ diagnosed and managed in patients taking Fosamax?

Diagnosis is based on clinical examination and imaging, revealing exposed necrotic bone in the jaw. Management includes conservative measures such as oral antimicrobial rinses, avoidance of surgical intervention, and discontinuation of the bisphosphonate when feasible. The FDA label advises discontinuation if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.